Q4 2024 Earnings Call Transcript March 11, 2025 Voyager Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...
LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...
Voyager 1 crossed into interstellar space in 2012, followed by Voyager 2 in 2018, making them the only spacecraft to operate ...
The same capsid in the VY1706 (tau silencing) gene therapy program achieved desired activity levels and was well-tolerated in three-month NHP studies. Voyager no longer anticipates filing an ...
Voyager program scientist at NASA Headquarters in Washington, in a statement. “Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics ...
IND filings expected in 2025 for GBA1 and FA programs - LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to ...
The farthest spacecraft from Earth are shutting off instruments in interstellar space, but their mission in interstellar space isn’t over yet ...
Voyager program scientist at NASA Headquarters in Washington. "Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics, but also a testament to ...